Published in Neth J Med on January 01, 1974
Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet (2000) 5.31
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Nomogram for derivation of renal threshold phosphate concentration. Lancet (1975) 3.20
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 2.23
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology (1994) 2.22
Diagnosis and treatment of adult intussusception. Am J Surg (1989) 2.20
Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 2.02
Mussels and Clams: A Seasonal Quarantine-Bicarbonate of Soda as a Factor in the Prevention of Mussel Poisoning. Cal West Med (1932) 2.02
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet (1983) 2.00
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet (1987) 1.90
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (1979) 1.78
Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet (1968) 1.77
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Cholesterol crystal embolization in the Netherlands. Arch Intern Med (1996) 1.74
Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg (1988) 1.72
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens. J Clin Pathol (1993) 1.66
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta (1983) 1.61
Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology (1996) 1.55
Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res (1987) 1.55
Satiety effects of cholecystokinin in humans. Gastroenterology (1994) 1.55
An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Neth J Med (2011) 1.53
Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association. Arch Intern Med (1995) 1.52
Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol (1995) 1.52
Serum gastrin and mucosal somatostatin in Helicobacter pylori-associated gastritis. Scand J Gastroenterol (1995) 1.47
The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene (1999) 1.47
Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol (1992) 1.46
Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol (1997) 1.46
Clinical presentation of Helicobacter pylori-positive and -negative functional dyspepsia. J Gastroenterol Hepatol (2000) 1.46
Gall bladder emptying in severe idiopathic constipation. Gut (1999) 1.43
The assessment of phosphate reabsorption. Clin Chim Acta (1969) 1.42
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
Lack of selective attendance of participants at skin cancer/melanoma screening clinics. J Am Acad Dermatol (1993) 1.39
[Consensus conference on osteoporosis]. Ned Tijdschr Geneeskd (1986) 1.39
Gallbladder motility after duodenum-preserving resection of the head of the pancreas. Scand J Gastroenterol (1997) 1.38
Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther (1987) 1.38
Ring 10 chromosome: 46,XX,r10(p15q26). Hum Genet (1978) 1.37
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Prospective randomized multicentre trial of proximal gastric vagotomy or truncal vagotomy and antrectomy for chronic duodenal ulcer: interim results. Br J Surg (1978) 1.31
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner (1987) 1.31
Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. Dig Dis Sci (1992) 1.29
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol (2009) 1.29
Cholecystokinin-octapeptidelike immunoreactivity in human plasma. Gastroenterology (1982) 1.29
Analysis of altered gene expression by differential display. Methods Enzymol (1995) 1.29
Proximal Crohn's disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis (2001) 1.26
The value of screening and central registration of families with familial adenomatous polyposis. A study of 82 families in The Netherlands. Dis Colon Rectum (1990) 1.25
Low-dose subcutaneous heparin versus oral anticoagulants in the prevention of postoperative deep-venous thrombosis. A controlled clinical trial. Lancet (1974) 1.24
Causes of failure in the surgical treatment of primary hyperparathyroidism: lessons from 51 successful reoperations. Br J Surg (1978) 1.24
The frequency of trisomy and translocation in Down's syndrome. J Pediatr (1967) 1.23
Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res (1988) 1.22
Natriuretic effect of calcitonin in man. N Engl J Med (1971) 1.21
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology (1990) 1.19
The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man. Eur J Pharmacol (1989) 1.19
Cloning and characterization of actin depolymerizing factor from Toxoplasma gondii. Mol Biochem Parasitol (1997) 1.19
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida. Infect Immun (1987) 1.19
Retinoblastoma with 13q- chromosomal deletion associated with maternal paracentric inversion of 13q. Science (1979) 1.18
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res (1994) 1.18
Urokinase receptor and colorectal cancer survival. Lancet (1994) 1.18
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 1.18
Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut (1989) 1.17
Influence of age and Helicobacter pylori infection on serum pepsinogens in healthy blood transfusion donors. Gut (1992) 1.16
Intussusception in children 5-15 years of age. Br J Surg (1987) 1.16
Analysis of 24-hour esophageal pressure and pH data in unselected patients with noncardiac chest pain. Gastroenterology (1990) 1.15
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab (1989) 1.15
Crohn's disease of the upper gastrointestinal tract. Neth J Med (1997) 1.14
Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res (2000) 1.14
Serum concentrations of immunoreactive calcitonin in patients with hypergastrinaemia. Digestion (1980) 1.13
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med (1987) 1.13
Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output. Gastroenterology (1985) 1.13
Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg (1986) 1.12
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut (1989) 1.11
Pancreatic enzyme response to a liquid meal and to hormonal stimulation. Correlation with plasma secretin and cholecystokinin levels. J Clin Invest (1985) 1.11
The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl (1997) 1.11
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol (2006) 1.10
A computerized method for rapid quantification of gallbladder volume from real-time sonograms. Radiology (1985) 1.10
Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br J Cancer (1998) 1.10
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res (1987) 1.09
Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol (1999) 1.09
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology (1991) 1.08
Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology (1984) 1.08
Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer (1987) 1.08
Xeroderma pigmentosum-Cockayne syndrome complex in two patients: absence of skin tumors despite severe deficiency of DNA excision repair. J Am Acad Dermatol (1993) 1.07
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06